Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Endometrial Carcinoma
Interventions: Arsenic trioxide; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetic Macular Edema
Interventions: REGN910-3, Intravitreal Aflibercept Injection (IAI); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 51
States / cities: Mesa, Arizona • Tucson, Arizona • Arcadia, California + 48 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV; Drug
Lead sponsor: Carl T. Hayden VA Medical Center; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy, Obesity, Diabetes, Healthy Volunteers, Atherosclerosis
Interventions: MR Imaging Techniques - 1, MR Imaging Techniques - 2, MR Imaging Techniques - 3, MR Imaging Techniques - 4; Device
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Endothelial Dysfunction
Interventions: Centella Asiatica, Placebo Comparator; Dietary Supplement
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 50 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Obesity, Pre-hypertension, Hypertension
Interventions: Whole Body Vibration Training, Hypocaloric diet, Whole body vibration training & diet; Other
Lead sponsor: Florida State University; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Diabetes Mellitus, Type 2, Hyperuricemia
Interventions: Low-fructose diet, isocaloric, Allopurinol, Placebo, Low-fructose, hypocaloric; Other · Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 40 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Perimenopause
Interventions: Resistance Training Intervention; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Rheumatoid Arthritis, Healthy
Interventions: Etanercept; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fuchs' Endothelial Dystrophy, Corneal Edema
Interventions: Endothelial keratoplasty, PRGF; Procedure · Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Indianapolis, Indiana

Conditions: HIV
Interventions: MRI, L-NMMA, Acetylcholine; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Health, Obesity
Interventions: Low-Carbohydrate (Modified Atkins) Diet, Low-Fat (Heart Healthy) Diet; Dietary Supplement
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Disease, Endothelial Function
Interventions: Hydroxytyrosol, the active ingredient in olive oil., Placebo, Nutrition counseling, Endopat; Dietary Supplement · Behavioral · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Abdominal Surgery, Thoracic Surgery
Interventions: Endothelial Function Test; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Germ Cell Cancer
Interventions: Endo-PAT2000 testing; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Preeclampsia, Preeclampsia Postpartum
Interventions: Eplerenone; Drug
Lead sponsor: Anna Stanhewicz, PhD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Endometrial Carcinoma
Interventions: carboplatin, paclitaxel, and bevacizumab; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Fuchs Endothelial Corneal Dystrophy
Interventions: N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 21 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sarcoma
Interventions: OMBRABULIN (AVE8062), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 6
States / cities: Santa Monica, California • Orlando, Florida • Maywood, Illinois + 3 more

Conditions: Elevated Blood Pressure, Hypertension
Interventions: Boxing Training, Control flexibility; Other
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Aging, Arterial Stiffness, Endothelial Dysfunction, Hypertension, Cognitive Decline
Interventions: Experimental: Nitrate-containing, Placebo: Nitrate-depleted; Drug
Lead sponsor: Gary L. Pierce, PhD; Other
Eligibility: 50 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Cardiac Allograft Vasculopathy, Antibody Mediated Rejection
Interventions: Optical Coherence Tomography, Acetylcholine, Brachial Artery Flow Mediated Dilation; Device · Drug · Procedure
Lead sponsor: Gladwin, Mark, MD; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetic Macular Edema
Interventions: intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 54
States / cities: Campbell, California • Glendale, California • Loma Linda, California + 46 more

Conditions: Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
Interventions: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2032
U.S. locations: 9
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 5 more

Search by objective public record fields.

Trisenox® in Women With Metastatic Endometrial Cancer

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

New Heart Imaging Techniques to Evaluate Possible Heart Disease

Centella Asiatica in Older Adults

Diet and Whole-body Vibration Training on Cardiovascular and Autonomic Function

Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid

Hemodynamics After Resistance Training

The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept

Plasma Rich in Growth Factors in Corneal Endothelial Transplantation

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

Effects of the Atkins Diet Versus a Low Fat Diet on Inflammation

Olive Oil and Cardiovascular Health

Perioperative Kinetics of Reactive Hyperemia Using Noninvasive Digital Thermal Monitoring

Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls

Vascular Effects of High-Salt After Preeclampsia

Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies

Clinical Effectiveness of Boxing Training in Individuals With Elevated Blood Pressure or Stage 1 Hypertension

Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study

Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation

DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

The DISCOVER INOCA Prospective Multi-center Registry